{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:01:11Z","timestamp":1793257271892,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"EuroQol","award":["EQ 20170510"],"award-info":[{"award-number":["EQ 20170510"]}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"crossref","award":["1768005"],"award-info":[{"award-number":["1768005"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"crossref","award":["P-2018-7046"],"award-info":[{"award-number":["P-2018-7046"]}],"id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","award":["FR 17 10 507"],"award-info":[{"award-number":["FR 17 10 507"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"crossref","award":["1868106"],"award-info":[{"award-number":["1868106"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"crossref"}]},{"name":"BMS","award":["1768053"],"award-info":[{"award-number":["1768053"]}]},{"name":"GSK","award":["Contract 05\/07\/2018"],"award-info":[{"award-number":["Contract 05\/07\/2018"]}]},{"DOI":"10.13039\/100015756","name":"Janssen Cilag","doi-asserted-by":"crossref","award":["1768065"],"award-info":[{"award-number":["1768065"]}],"id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MSD","award":["1768064"],"award-info":[{"award-number":["1768064"]}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"crossref","award":["Contract 11\/24\/2017"],"award-info":[{"award-number":["Contract 11\/24\/2017"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","award":["1768051"],"award-info":[{"award-number":["1768051"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","award":["Contract 01\/08\/2018"],"award-info":[{"award-number":["Contract 01\/08\/2018"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","award":["1768122"],"award-info":[{"award-number":["1768122"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40273-019-00876-4","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T22:02:30Z","timestamp":1578434550000},"page":"413-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["A French Value Set for the EQ-5D-5L"],"prefix":"10.1007","volume":"38","author":[{"given":"Luiz Flavio","family":"Andrade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel Ramos","family":"Goni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Oppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5941-6823","authenticated-orcid":false,"given":"G\u00e9rard","family":"de Pouvourville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"876_CR1","unstructured":"Decree n\u00b0 2012-1116, October 2, 2012, defining the health economics missions of the High Health Authority. French Republic Offical Gazette n\u00b0 0231, October 4 2012, page 15222, text n\u00b0 8. https:\/\/www.legifrance.gouv.fr\/."},{"key":"876_CR2","unstructured":"Decision n\u00b02013.0111\/DC\/SEESP, September 18, 2013: Collge of the High Health Authority relative to the significiant impact on expenditures for the National Sickness Fund triggering the need for an economic assessment of health products claiming an improvement\/expected of Medical Serivce Rendered of I, II or III. https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2013-09\/c_2013_0111_definition_impact_significatif.pdf."},{"key":"876_CR3","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Choices in methods for economic evaluation. Department of Economics and Public Health Assessment. Haute Autorit\u00e9 de Sant\u00e9; Oct 2012. https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2012-10\/choices_in_methods_for_economic_evaluation.pdf."},{"issue":"1","key":"876_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10198-011-0351-x","volume":"14","author":"J Chevalier","year":"2013","unstructured":"Chevalier J, de Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ. 2013;14(1):57\u201366.","journal-title":"Eur J Health Econ."},{"key":"876_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1023\/A:1008830115246","volume":"7","author":"N Costet","year":"1998","unstructured":"Costet N, Le Gal\u00e8s C, Buron C, Kinkor F, Mesbath M, et al. French cross-cultural adaptation of the Health Utilities Indexes mark 2 (HUI2) and 3 (HUI3) classification systems. Qual Life Res. 1998;7:245\u201356.","journal-title":"Qual Life Res"},{"issue":"4\u20135","key":"876_CR6","first-page":"71","volume":"150\u20131","author":"C Le Gales","year":"2001","unstructured":"Le Gales C, Buron C, Costet N, Rosman C, Slama G. D\u00e9veloppement d\u2019un index d\u2019\u00e9tats de sant\u00e9 par les utilit\u00e9s en population fran\u00e7aise: le Health Utilities Index. Economie et pr\u00e9vision. 2001;150\u20131(4\u20135):71\u201387.","journal-title":"Economie et pr\u00e9vision."},{"issue":"5","key":"876_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/14737167.2017.1289088","volume":"17","author":"FF Hamers","year":"2017","unstructured":"Hamers FF, Ghabri S, Le Gales C. Health-state utility estimates for health technology assessment: a review of the manufacturers\u2019 submissions to the French National Authority for Health. Expert Rev Pharmacoecon Outcomes Res. 2017;17(5):489\u201394.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"876_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40273-018-0623-8","volume":"36","author":"MF Janssen","year":"2018","unstructured":"Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. PharmacoEconomics. 2018;36:675\u201397.","journal-title":"PharmacoEconomics."},{"key":"876_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/01.mlr.0000254515.63841.81","volume":"45","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care. 2007;45:259\u201363.","journal-title":"Med Care"},{"key":"876_CR10","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","volume":"22","author":"MF Janssen","year":"2013","unstructured":"Janssen MF, Simon Pickard A, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22:1717\u201327.","journal-title":"Qual Life Res"},{"issue":"74","key":"876_CR11","first-page":"4","volume":"12","author":"BC Agborsangaya","year":"2014","unstructured":"Agborsangaya BC, Lahtinen M, Cooke T, Johnson JA. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health Qual Life Outcomes. 2014;12(74):4.","journal-title":"Health Qual Life Outcomes."},{"key":"876_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12955-015-0356-8","volume":"13","author":"Y Feng","year":"2015","unstructured":"Feng Y, Devlin N, Herdman M. Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare? Health Qual Life Outcomes. 2015;13:171.","journal-title":"Health Qual Life Outcomes."},{"issue":"4","key":"876_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jval.2014.04.002","volume":"17","author":"M Oppe","year":"2014","unstructured":"Oppe M, Devlin NJ, van Hout B, Krabbe PF, de Charro F. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health. 2014;17(4):445\u201353.","journal-title":"Value Health."},{"issue":"1","key":"876_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jval.2018.05.010","volume":"22","author":"Elly Stolk","year":"2019","unstructured":"Stolk E, Ludwig K, Rand K, van Hout B, Ramos Go\u00f1i JM. Overview, update and lessons learned from the international EQ-5D-5L valuation work: version 2 of the EQ-5D-5L valuation protocol. Value Health. 2019;22(1):23\u201330.","journal-title":"Value in Health"},{"key":"876_CR15","unstructured":"Commission for Health Economics and Public Health Assessments (CEESP). Minutes of Tuesday, June 13, 2017 session. https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2017-09\/compte-rendu_ceesp_13_juin_2017.pdf."},{"issue":"5","key":"876_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health."},{"key":"876_CR17","unstructured":"Oppe M, van Hout B. The \u201cpower\u201d of eliciting EQ-5D-5L values: the experimental design of the EQ-VT. EuroQol Working Paper Series Number 17003, October 2017. https:\/\/euroqol.org\/wp-content\/uploads\/2016\/10\/EuroQol-Working-Paper-Series-Manuscript-17003-Mark-Oppe.pdf."},{"issue":"S1","key":"876_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10198-013-0503-2","volume":"14","author":"Bas M. F. Janssen","year":"2013","unstructured":"Janssen MF, Oppe M, Versteegh M, Stolk E. Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ. 2013;14(Suppl 1):S5\u2013S13.","journal-title":"The European Journal of Health Economics"},{"key":"876_CR19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/hec.1596","volume":"20","author":"NJ Devlin","year":"2011","unstructured":"Devlin NJ, Tsuchiya A, Buckingham K, Tilling C. A uniform time trade off method for states better and worse than dead: feasibility study of the \u2018lead time\u2019 approach. Health Econ. 2011;20:348\u201361.","journal-title":"Health Econ"},{"issue":"6","key":"876_CR20","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jval.2017.10.013","volume":"21","author":"E Wong","year":"2018","unstructured":"Wong E, Shah K, Cheung AWL, Wong AYK, Visser M, Stolk E. Evaluation of split version and feedback module on the improvement of time trade-off data. Value Health. 2018;21(6):732\u201341.","journal-title":"Value Health."},{"key":"876_CR21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jval.2016.10.012","volume":"20","author":"JM Ramos-Go\u00f1i","year":"2016","unstructured":"Ramos-Go\u00f1i JM, Oppe M, Slaap B, Busschbach JJV, Stolk E. Quality control process for EQ-5D-5L valuation studies. Value Health. 2016;20:466\u201373.","journal-title":"Value Health."},{"issue":"7","key":"876_CR22","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1097\/MLR.0000000000000283","volume":"55","author":"JM Ramos-Go\u00f1i","year":"2017","unstructured":"Ramos-Go\u00f1i JM, Pinto-Prades JL, Oppe M, Cabas\u00e9s JM, Serrano-Aguilar P, et al. Valuation and modeling of EQ-5D-5L health states using a hybrid approach. Med Care. 2017;55(7):e51\u20138.","journal-title":"Med Care"},{"key":"876_CR23","unstructured":"Ramos-Go\u00f1i JM, Craig B, Oppe M, van Hout B. Combining continuous and dichotomous responses in a hybrid model. 2016. EuroQol Working Paper Series #16002. https:\/\/euroqol.org\/"},{"key":"876_CR24","unstructured":"National Institute for Statistics and Economic Studies (INSSE). Total population age and sex, January 1st, 2018. https:\/\/www.insee.fr\/fr\/statistiques\/1892086?sommaire=1912926."},{"issue":"10","key":"876_CR25","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M. Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727.","journal-title":"Quality of Life Research"},{"issue":"6","key":"876_CR26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","volume":"36","author":"Kristina Ludwig","year":"2018","unstructured":"Ludwig K, Graf vonder Schulenburg JM, Greiner W. German Value Set for the EQ-5D-5L. Pharmacoeconomics. 2018;36:663.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"876_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","volume":"27","author":"NJ Devlin","year":"2017","unstructured":"Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ5D-5L value set for England. Health Econ. 2017;27(1):7\u201322.","journal-title":"Health Econ"},{"key":"876_CR28","doi-asserted-by":"crossref","unstructured":"Versteegh MM, Vermeulen KM, Evers S, Ardine de Wit, Prenger R, et al. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19:343-352.","DOI":"10.1016\/j.jval.2016.01.003"},{"issue":"11","key":"876_CR29","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s40273-018-0690-x","volume":"36","author":"A Hobbins","year":"2018","unstructured":"Hobbins A, Barry L, Kelleher D, Shah K, Devlin N, Ramos Goni JM, et al. Utility values for health states in Ireland: a value set for the EQ-5D-5L. PharmacoEconomics. 2018;36(11):1345\u201353.","journal-title":"PharmacoEconomics."},{"issue":"5","key":"876_CR30","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jval.2017.10.023","volume":"21","author":"JM Ramos-Go\u00f1i","year":"2018","unstructured":"Ramos-Go\u00f1i JM, Craig BM, Oppe M, Ramallo-Fari\u00f1a Y, Pinto-Prades JL, Luo N, et al. Handling data quality issues to estimate the Spanish EQ-5D-5L value set using a hybrid interval regression approach. Value Health. 2018;21(5):596\u2013604.","journal-title":"Value Health."},{"issue":"1","key":"876_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jval.2017.09.004","volume":"21","author":"AM Hernandez","year":"2018","unstructured":"Hernandez AM, Wailoo A, Grimm S, Pudney S, Gomes M, et al. EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. Value in Health. 2018;21(1):49\u201356.","journal-title":"Value in Health."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00876-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00876-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00876-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T20:51:57Z","timestamp":1609966317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00876-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["876"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00876-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"8 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by EuroQol (EQ 20170510), as well as Abbvie (1768005), Allergan (P-2018-7046), Amgen (FR 17 10 507), Biogen (1868106), BMS (1768053), GSK (Contract 05\/07\/2018), Janssen Cilag (1768065), MSD, Lilly (Contract 11\/24\/2017), Novartis (1768051), Roche (Contract 01\/08\/2018), and Sanofi (1768122). The ESSEC was the recipient of funds. Funding was unrestricted and companies have no claims on the data and the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"G\u00e9rard de Pouvourville was Full Professor at the ESSEC Business School at the time of this study. He has been, and is, a regular consultant for the funding companies, as a member of advisory boards on cost-effectiveness analyses. The ESSEC has also received funding to perform cost-effectiveness analysis. None of the existing funding has been related to developing value sets for quality-of-life questionnaires. The ESSEC is currently funded to perform a survey on the quality of life of French inflammatory bowel disease patients using EQ-5D-5L. The funding sources were Euroqol, Amgen, MSD, Janssen Cilag and Biogaran, through unrestricted research grants. Luiz Andrade was a research assistant at the time of the study and was employed by the ESSEC. He has no direct financial conflicts of interest. Kristina Ludwig worked as a freelancer for the EuroQol Research Foundation during the data collection phase of the study and has received research grants from the Foundation to conduct methodological research. She has received no direct payment from industrial sponsors for this study. As a collaborator of EuroQol and the main investigator of the German Value Set, she supports the EQ-5D-5L and the methodological choices made by the Foundation. Mark Oppe was an employee of the EuroQol Research Foundation at the time of the study, but now works for Axentiva Solutions, a consulting company based in Spain. He was a main contributor to the development of the EQ-5D-5L valuation methodology, specifically for the cTTO protocol, the Quality Control module, and the development of the hybrid methodology. Juan Manuel Ramos Goni is a member of EuroQol and founder of Axentiva Solutions. He has received no direct payment from industry sponsors for the French study. He also contributed to the development of the EQ-5D-5L valuation methodology, specifically for the development of the hybrid methodology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study has been declared to the Commission Nationale Informatique et Libert\u00e9 (CNIL) as MR003 type research, under number 225070 v 0. The research does not come under the general field of \u201cresearch organized to be applied to the human being with the aim of the development of biologic or medical knowledge\u201d and did not require submission to a Committee for the Protection of Persons (CPP). Informed consent of respondents was requested before the interview started, and the interview process could not start if potential respondents refused to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}